recent
elucid
rich
complex
microbiom
patient
cystic
fibrosi
cf
invigor
new
discuss
role
microbi
infect
cf
beyond
pathogen
classic
link
cf
like
pseudomona
aeruginosa
increas
number
studi
character
composit
airway
microbiota
patient
differ
cf
cohort
common
thread
emerg
across
studi
relationship
observ
featur
respiratori
microbiom
clinic
outcom
howev
extend
observ
clinic
realm
predict
manner
remain
challeng
sever
reason
includ
interpati
heterogen
airway
microbiota
composit
come
appreci
studi
studi
date
focus
bacteri
member
respiratori
microbiom
recent
investig
also
begun
character
fungal
viral
commun
cf
effort
import
microbi
kingdom
larg
ignor
schema
lung
microbiom
investig
addit
recent
studi
begun
explor
microbiom
organ
affect
cf
gastrointestin
tract
gut
dysfunct
anoth
promin
featur
cf
find
studi
may
import
clinic
implic
articl
highlight
recent
insight
rapidli
evolv
area
cf
microbiom
investig
advanc
knowledg
natur
microbi
dysbiosi
ie
alter
microbi
balanc
cf
reshap
conceptu
framework
within
role
infect
cf
long
consid
select
studi
discuss
contribut
current
understand
structur
composit
collect
function
cf
microbiota
relationship
diseas
benchmark
addit
challeng
opportun
present
recent
insight
discuss
term
knowledg
may
leverag
inform
care
patient
cf
advanc
sequencebas
analysi
microbi
genom
laid
foundat
techniqu
character
type
microbi
speci
present
sampl
bacteria
wide
use
approach
base
analysi
ribosom
rna
gene
whose
conserv
across
speci
along
polymorph
hypervari
region
gene
enabl
broad
detect
bacteria
present
sampl
phylogenet
ident
comprehens
discuss
regard
method
tool
studi
microbiom
includ
context
lung
diseas
reader
refer
recent
articl
area
uniqu
anatomi
lung
present
challeng
studi
microbiom
collect
lower
airway
sampl
requir
passag
upper
respiratori
tract
oropharynx
previous
rais
question
extent
oral
contamin
sampl
howev
sever
studi
establish
microbiota
identifi
lower
respiratori
specimen
distinguish
upper
airway
microbiota
especi
nasopharyng
measur
divers
also
type
rel
abund
specif
bacteri
group
moreov
architectur
bronchial
airway
lead
region
differ
lung
biolog
airway
microenviron
even
healthi
state
cf
like
pattern
dysbiosi
greatli
influenc
alter
airway
milieu
relat
cf
transmembran
receptor
dysfunct
subsequ
chang
mucu
clearanc
cystic
fibrosi
respiratori
microbiom
bacteria
culturebas
investig
bronchiectasi
chronic
infect
wellrecogn
clinic
featur
cf
contribut
diseas
morbid
mortal
although
well
establish
p
aeruginosa
import
pathogen
cf
lung
diseas
bacteria
also
contribut
pulmonari
morbid
cf
includ
burkholderia
cepacia
complex
methicillinresist
staphylococcu
aureu
certain
nontubercul
mycobacteria
mycobacterium
abscessu
complex
mycobacterium
avium
complex
microbiolog
featur
organ
includ
factor
respons
virul
resist
antimicrobi
therapi
extens
studi
addit
potenti
pathogen
associ
cf
includ
stenotrophomona
maltophilia
achromobact
spp
includ
achromobact
xylosoxidan
achromobact
ruhlandii
difficult
treat
role
anaerob
bacteria
cf
lung
diseas
remain
uncertain
frequent
identifi
preval
culturetarget
cultureindepend
method
current
data
support
argument
anaerob
play
import
role
cf
airway
microenviron
especi
given
steep
oxygen
gradient
present
addit
contribut
cf
antibiot
resistom
ie
collect
antibiot
resist
gene
microorgan
certain
preval
anaerob
speci
produc
quorumsens
molecul
mediat
interspeci
signal
pathway
potenti
influenc
virul
characterist
pathogen
like
p
aeruginosa
recent
evid
also
suggest
metabol
product
associ
anaerob
includ
shortchain
fatti
acid
detect
airway
specimen
may
increas
releas
interleukin
il
granulocytemacrophag
colonystimul
factor
reduc
induc
no
nitric
oxid
synthas
gene
express
thu
anaerob
bacteria
may
group
keyston
organ
collect
larg
influenc
cf
pulmonari
ecosystem
cultureindepend
investig
within
past
year
expand
reshap
tradit
view
cf
airway
microbiolog
across
crosssect
longitudin
studi
cf
respiratori
sampl
sever
similar
observ
made
first
studi
respiratori
sampl
young
children
cf
note
sever
distinct
bacteri
group
present
directli
sampl
cfaffect
lung
tissu
bronchoalveolar
lavag
fluid
coupl
knowledg
structur
physiolog
function
lung
compromis
earli
life
cfaffect
children
suggest
direct
relationship
earli
develop
microbi
dysbiosi
lung
clinic
outcom
second
airway
bacteri
divers
patient
cf
greatest
earli
life
adolesc
declin
thereaft
adulthood
observ
made
crosssect
longitudin
analys
includ
birth
cohort
studi
found
bacteri
divers
first
year
life
influenc
feed
habit
declin
specif
bacteria
haemophilu
preced
colon
p
aeruginosa
similar
trend
observ
crosssect
analys
across
differ
age
group
select
pressur
cumul
cours
antibiot
predomin
factor
shape
chang
bacteri
commun
structur
third
studi
adult
cf
observ
great
heterogen
among
patient
composit
bacteri
commun
identifi
airway
sampl
mostli
sputum
type
rel
abund
differ
bacteri
group
detect
vari
consider
patient
shown
repres
exampl
one
studi
fig
anoth
consist
find
bacteri
group
preval
within
patient
also
tend
vari
substanti
rel
abund
time
preval
commun
identifi
cultureindepend
investig
mirror
speci
genera
detect
clinic
cultur
p
aeruginosa
burkholderia
staphylococcu
preval
bacteri
group
essenc
repres
core
member
cf
respiratori
microbiom
result
cultureindepend
analys
suggest
addit
bacteri
group
usual
detect
typic
cf
clinic
cultur
method
compris
core
exampl
use
approach
partit
distribut
speci
base
statist
varianceabund
ratio
investig
one
studi
report
addit
pseudomona
anaerob
speci
member
porphyromona
prevotella
veillonella
genera
also
contribut
studi
cohort
core
group
microbiota
total
taxa
genera
find
contrast
greater
rang
bacteri
group
taxa
genera
compris
satellit
group
microbiota
correl
clinic
factor
howev
whether
satellit
speci
nonetheless
contribut
ecolog
interact
import
within
cf
microbiom
remain
outstand
question
implic
find
molecularbas
bacteri
commun
signatur
distinguish
patient
clinic
difficult
ascertain
exampl
cf
pulmonari
exacerb
consist
chang
airway
bacteri
burden
commun
composit
observ
among
patient
within
given
studi
compar
across
studi
patient
show
mark
shift
respiratori
bacteri
commun
structur
given
exacerb
wherea
other
show
littl
chang
despit
clinic
symptom
suggest
event
moreov
patient
across
differ
studi
shown
exacerbationrel
reduct
abund
baselin
predomin
speci
suggest
increas
abund
less
preval
microbiota
member
may
play
greater
role
certain
exacerb
addit
antibiot
treatment
exacerb
caus
sustain
shift
bacteri
commun
structur
follow
exacerb
cf
airway
microbiom
gener
resili
perturb
commun
reassembl
recoveri
resembl
patient
baselin
commun
structur
character
fungal
microbi
commun
mycobiom
gener
lag
behind
studi
bacteria
recent
advanc
made
respiratori
studi
sever
factor
make
identifi
fungi
analysi
mycobiom
challeng
similar
bacteria
fungal
speci
difficult
possibl
cultur
applic
highthroughput
sequenc
approach
better
delin
divers
fungal
speci
harbor
lung
context
respiratori
diseas
howev
approach
sampl
prepar
extract
fungal
dna
choic
primer
amplifi
fungal
sequenc
nonuniform
across
studi
influenc
readout
fungal
composit
moreov
exist
refer
databas
compar
fungal
sequenc
less
rich
robust
bacteria
eg
ribosom
rna
databas
limit
analyt
effort
investig
consid
studi
therefor
cogniz
factor
could
bia
limit
fungal
commun
character
notwithstand
challeng
sever
studi
explor
respiratori
mycobiom
cf
studi
sputum
sampl
patient
cf
identifi
fungal
taxa
detect
mycolog
cultur
addit
candida
albican
aspergillu
fumigatu
fungal
speci
genera
identifi
includ
speci
candida
aspergillu
penicillium
malassezia
kluyveromyc
anoth
studi
subject
cf
found
mixtur
candida
malassezia
speci
domin
fungal
sequenc
read
sputum
although
sampl
collect
time
admiss
complet
antibacteri
therapi
could
influenc
find
one
largest
studi
date
involv
patient
found
number
fungal
speci
detect
cf
sputum
higher
bacteria
also
fluctuat
much
time
investig
conclud
suggest
inhal
exposur
greater
drive
factor
detect
fungi
establish
fungal
colon
cf
airway
cultureindepend
nonsequenc
approach
identifi
fungal
speci
denatur
highperform
liquid
chromatographi
also
explor
use
cf
sputa
howev
util
approach
compar
other
remain
uncertain
infect
rna
virus
eg
rhinoviru
coronaviru
parainfluenza
import
trigger
cf
pulmonari
exacerb
howev
studi
examin
respiratori
virom
cf
part
challeng
conduct
comprehens
viral
sequenc
studi
sever
studi
focus
bacteriophag
popul
airway
dna
virus
infect
specif
bacteria
specif
phage
studi
altern
therapeut
approach
potenti
target
particular
bacteri
pathogen
like
p
aeruginosa
metagenom
studi
provid
comprehens
pictur
dna
virus
respiratori
tract
patient
cf
note
cfassoci
phage
commun
highli
similar
contrast
found
patient
without
cf
find
like
reflect
rang
bacteri
speci
select
cf
lung
high
phagebacteria
ratio
describ
varieti
mucos
environ
includ
human
gingiv
sampl
vitro
studi
shown
phage
adher
mucu
mediat
bind
interact
immunoglobulinlik
domain
phage
capsid
glycan
residu
mucin
glycoprotein
pretreat
mucusproduc
cell
line
phage
led
subsequ
decreas
bacteri
attach
escherichia
coli
cell
find
led
investig
propos
bacteriophag
adher
mucu
may
serv
form
antibacteri
immun
along
mucos
surfac
howev
potenti
signific
system
extrapol
cf
lung
remain
unclear
data
also
suggest
phage
may
function
synergist
antibiot
wherein
antibiot
stimul
phage
product
andor
activ
aid
bacteri
kill
lytic
activ
temper
phage
may
also
preserv
longterm
chronic
p
aeruginosa
infect
potenti
contribut
control
p
aeruginosa
densiti
composit
studi
microbiota
harbor
within
patient
cf
broaden
knowledg
microbi
divers
associ
diseas
howev
like
function
metabol
featur
encod
express
collect
microbi
commun
span
specieslevel
differ
taxonom
composit
nonuniform
across
patient
evid
crossphylogeni
share
gene
function
found
gut
microbiom
via
known
mechan
horizont
gene
transfer
bacteria
serv
premis
develop
silico
approach
determin
function
capac
bacteri
microbiota
base
metagenom
predict
use
combin
metagenom
metatranscriptom
approach
sequenc
dna
rna
perform
quinn
colleagu
examin
function
capac
microbiota
detect
sputa
patient
cf
enrich
function
express
cfassoci
organ
includ
amino
acid
catabol
folat
biosynthesi
nitrat
reduct
pathway
nitrat
reduct
pathway
larg
encod
pseudomona
rothia
data
also
suggest
ammonia
may
accumul
airway
environ
oxid
pathway
involv
nitrogen
cycl
incomplet
artifici
cultur
system
also
appli
attempt
simul
studi
cf
microbialrel
physiolog
airway
one
approach
use
glass
capillari
tube
instil
artifici
sputum
medium
intend
mimic
cf
physiolog
condit
inocul
bacteri
strain
deriv
patient
cf
collect
serial
period
clinic
stabil
exacerb
use
combin
techniqu
evalu
physiolog
system
investig
observ
increas
ga
product
reduct
ph
onset
exacerb
parallel
analysi
microbi
commun
note
increas
abund
ferment
anaerob
suggest
metabol
activ
organ
may
contribut
develop
exacerb
although
studi
respiratori
microbiota
domin
cf
microbiom
studi
recent
investig
also
begun
character
analyz
relationship
gastrointestin
bacteri
microbiota
clinic
diseas
marker
profil
airway
bacteri
commun
composit
gastrointestin
complic
cf
signific
caus
diseas
morbid
problem
beyond
pancreat
insuffici
often
difficult
manag
two
studi
involv
cohort
patient
cf
found
number
enterobacteriacea
margin
higher
cf
fecal
sampl
wherea
signific
underrepresent
bifidobacterium
member
clostridium
cluster
xiva
twoyear
longitudin
analysi
patient
cf
healthi
sibl
observ
trend
toward
lower
speci
rich
tempor
stabil
cf
fecal
microbiota
pattern
gut
respiratori
microbiom
develop
earli
life
children
cf
report
studi
singl
birth
cohort
although
number
subject
small
investig
observ
initi
diversif
gut
respiratori
microbiota
composit
follow
subsequ
shift
commun
composit
relat
chang
diet
name
cessat
breastfeed
introduct
solid
food
although
children
without
cf
includ
control
group
comparison
studi
observ
consist
normal
pattern
gut
microbiom
matur
earli
life
healthi
infant
chang
diet
also
influenc
respiratori
microbiota
composit
indic
link
nutrit
intak
decreas
specif
bacteri
genera
gut
parabacteroid
respiratori
tract
haemophilu
preced
airway
colon
p
aeruginosa
anoth
interest
observ
intestin
respiratori
bacteri
commun
structur
first
month
life
associ
occurr
cf
exacerb
time
frame
find
type
studi
well
intervent
trial
use
probiot
speci
suggest
manipul
gut
microbiom
foster
less
proinflammatori
environ
could
avenu
mitig
pulmonari
morbid
cf
new
insight
afford
studi
describ
earlier
provid
foundat
address
sever
import
question
pertain
microbiolog
cf
clinician
continu
explor
longterm
dynam
airway
bacteri
commun
structur
focu
better
elucid
relationship
decreas
commun
divers
advanc
patient
age
lung
diseas
intrigu
question
whether
maintain
divers
commun
might
posit
impact
lung
health
whether
novel
treatment
strategi
eg
target
speciesspecif
antimicrobi
therapi
may
enabl
mainten
healthier
airway
commun
complet
understand
shortterm
commun
dynam
may
identifi
reproduc
chang
commun
structur
andor
activ
associ
chang
patient
clinic
condit
multiom
analys
identifi
exampl
biomark
impend
exacerb
great
interest
determin
whether
monitor
real
time
exploit
prevent
better
manag
event
similarli
specif
pattern
commun
chang
may
identifi
predict
exacerb
sever
andor
recoveri
move
forward
import
complement
grow
understand
bacteri
ecolog
cf
airway
attent
broader
microbi
commun
includ
viral
fungal
speci
advanc
appreci
microbi
interact
drive
activ
polymicrobi
commun
expect
provid
opportun
novel
therapi
addit
continu
investig
relationship
disord
gut
microbiota
lung
disord
cf
potenti
translat
creativ
manag
strategi
gener
mechanist
hypothes
address
cf
pathobiolog
